This phase 3 clinical trial assessed the efficacy and safety of NA tislelizumab (an anti-PD1 monoclonal antibody) in patients with resectable stage II-IIIA NSCLC (n = 452), with EGFR and ALK alterations excluded. The gene discussed is ALK; the disease is non-small cell lung carcinoma.